Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial
Kolon TissueGene’s knee osteoarthritis cell and gene therapy, TG-C, has failed to achieve statistical significance on its primary endpoints in its...
Search results for "placebo effect"
Surgery Is Just the First Step in Lung Cancer: Why EGFR Mutation Testing Matters
Lung cancer is the second most commonly diagnosed cancer in South Korea and the leading cause of cancer mortality, making it one of the country's...
“I Dream of an Ordinary Life”: Expanded Insurance Coverage Brings New Hope to Dravet Syndrome Families
“Until just before my daughter turned 2, she frequently suffered not only febrile seizures but also afebrile seizures.
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide
JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
550 Days in Limbo: Groups Demand 100-Day Fast-Track Insurance Coverage for Breakthrough PAH Drug Winrevair
With national health insurance coverage for the new pulmonary arterial hypertension treatment Winrevair (active...
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by...
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C...
Antihistamines Provide Minimal Relief for Atopic Dermatitis Itch, Study Finds
Antihistamines commonly used to ease itching from atopic dermatitis do not deliver a large enough benefit for patients...
Why Bones Break Before Osteoporosis Sets In: The Hidden Risk Behind Normal Scans
"I slipped and broke my wrist." "I fell, broke my hip, and even had to get surgery." Most people chalk these injuries...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.